Glenmark Pharmaceuticals Limited · NSE:GLENMARK
Glenmark Pharmaceuticals — Q4 FY26 Earnings Presentation
14 slides from Glenmark Pharmaceuticals's earnings presentation, May 29, 2026
Slide 1: Stock exchange filing cover letter
May 29, 2026 To, To, National Stock Exchange of India Limited, BSE Limited, “Exchange Plaza”, Corporate Relationship Department, 5th Floor, Plot No. C/1, G Block, 2nd Floor, New Trading Ring, Bandra- Kurla Complex Bandra (East), Mumbai P.J. Towers, Dalal Street, – 400 051 Mumbai – 400 001 Scrip Name
Slide 2: Investor Presentation Q4 FY26
Investor Presentation Q4 FY26 29 May 2026
Slide 3: Disclaimer
Disclaimer This document has been prepared by Glenmark Pharmaceuticals Ltd. and the information, statements and analysis made in this document describing the Company’s or its affiliates’ objectives, projections and estimates are forward looking statements. Forward-looking statements are all statemen
Slide 4: Summary – Q4 FY26
Summary – Q4 FY26 “FY26 has been a defining year in Glenmark’s evolution. We delivered Consolidated strong business performance while making meaningful progress against the • Consolidated Revenue of Rs. 37,706 million Revenue • YoY growth of 15.8% strategic priorities that will shape our future. The
Slide 5: Key Highlights – FY26
Key Highlights – FY26 Accelerated Oncology IGI secured a landmark India business delivered business expansion in Multiple differentiated licensing deal with AbbVie strong outperformance in India and Emerging product launches in India for ISB 2001 secondary sales Markets USD 700 million upfront payme
Slide 6: Consolidated Revenue – Q4 and 12M FY26
Consolidated Revenue – Q4 and 12M FY26 Fourth Quarter ended March 31 Twelve Months ended March 31 Rs. million FY 2026 FY 2025 YoY Growth FY 2026 FY 2025 YoY Growth India 10,201 9,430 8.2% 37,237 44,845 -17.0% North America # 9,248 7,146 29.4% 71,390 30,172 136.6% Europe 8,907 7,335 21.4% 31,007 28,4
Slide 7: India
India Revenue (Rs. million) Significant outperformance compared to YoY: 8.2% IPM in terms of secondary sales 10,201 9,430 Recorded a strong year for its Oncology business Continues to be top-ranked in its core therapeutic areas Q4 FY26 Q4 FY25 YoY: -17% Launched GLIPIQ® (semaglutide) in both 44,845
Slide 8: North America
North America Revenue (Rs. million)# Launched 13 new products in FY26 across oral YoY: 29.4% solids, injectables, Respiratory 9,248 7,146 First generic approval of FloVent® HFA 44 mcg with 180-day CGT exclusivity Fluticasone Nasal Spray [OTC] approved, three additional Respiratory ANDAs filed Q4 FY2
Slide 9: Europe
Europe Revenue (Rs. million) YoY: 21.4% Strong growth in branded markets / products 8,907 7,335 Growing western European markets – Germany, the Netherlands and Italy Sustained momentum in RYALTRIS® sales across the region Q4 FY26 Q4 FY25 YoY: 8.9% WINLEVI® gained traction since its launch in the 31,
Slide 10: Emerging Markets
Emerging Markets Revenue (Rs. million) Continued outperformance in Russia YoY: 13.7% Dermatology market 8,979 7,898 High single-digit secondary sales growth in LATAM and MEA markets during Q4 RYALTRIS® continues to be the leading nasal spray in the region Q4 FY26 Q4 FY25 YoY: 4.5% RYALTRIS® launched
Slide 11: Global Innovative Portfolio Update
Global Innovative Portfolio Update QiNHAYO TRASTUZUMAB RYALTRIS® WINLEVI® (ENVAFOLIMAB) REZETECAN AUMOLERTINIB • Commercialized in • Launched in the • Marketing • First wave of MA • Submitted MA 55 markets UK in Q1 FY26; authorization applications to applications for strong uptake applications filed
Slide 12: Diversity of Immune Cell Engagement Across Hematologic & Solid Tumor Indications, and Autoimmune Diseases
Diversity of Immune Cell Engagement Across Hematologic & Solid Tumor Indications, and Autoimmune Diseases ONCOLOGY ASSET DESCRIPTION INDICATION DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 RIGHTS CD38 x BCMA x CD3 Multiple * ISB 2001 (ABBV-2001) Trispecific Myeloma T -cell engager Multispecific imm
Slide 13: IGI - Key updates
IGI - Key updates • ISB 2001/ABBV-2001 o ISB 2001/ABBV-2001 patient enrolment in Phase 1 Dose Expansion is progressing rapidly with the goal to determine an optimal RP2D regimen. Efficacy and safety data continue to remain promising and consistent with what was previously reported. • ISB 2301 (Multi
Slide 14: Thank you
G glenmark new way for a new world
Glenmark Pharmaceuticals — Q4 FY26 Earnings Presentation on 6ix